top of page
Home / Information / Brigatinib
Brigatinib
Brigatinib is a 2nd generation TKI developed by Takeda. The recommended dose is 180mg taken daily.
Documents
Name
Summary of Contents
Action
NICE Approves Brigatinib
This document explains Brigatinib for treating ALK+ NSCLC after crizotinib
bottom of page